Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.185 USD | -4.44% | +3.95% | +17.33% |
May. 15 | Canaccord Genuity Trims Price Target on Passage Bio to $13 From $14, Maintains Buy Rating | MT |
May. 14 | Passage Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.33% | 73.04M | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+1.14% | 22.78B | |
-10.95% | 17.96B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+2.44% | 13.58B | |
+27.89% | 11.66B |
- Stock Market
- Equities
- PASG Stock
- News Passage Bio, Inc.
- Passage Bio Reports 'Positive' Interim Results of Gene Therapy Trial for GM1 Gangliosidosis in Children; Shares Rise